AI Portfolio Summary
In 2025 Q4, Propel Bio Management, LLC maintained a portfolio of 24 distinct positions. The most significant new addition to the portfolio was KYVERNA THERAPEUTICS, which now represents 5.35% of the total fund value. They heavily accumulated shares in PHATHOM PHARMACEUTIC, increasing their position by 34.0%. Conversely, Propel Bio Management, LLC completely exited their position in AKERO THERAPEUTICS I.
Total Positions
24
Quarter
2025 Q4
Top Holding
PAGP (20.8%)
Top 10 Concentration
83.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-24 of 24
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PAGP
PLAINS GP HLDGS...
|
Bond/Debt | 20.79% | 23.23% |
#1
Prev: #1
|
8.3 | no change | no change |
P
S
|
1,272,360 | $24,352,970 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 16.07% | 11.94% |
#2
Prev: #2
|
6.4 | no change | no change |
P
S
|
3,786,425 | $18,818,532 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 10.49% | 6.51% |
#3
3
Prev: #6
|
6.3 | 187,991 | 34.0% |
P
S
|
740,918 | $12,291,830 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 7.51% | 1.94% |
#4
11
Prev: #15
|
5.3 | 192,531 | 213.9% |
P
S
|
282,531 | $8,792,365 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIST
MILESTONE PHARM...
|
Healthcare | 7.10% | 10.26% |
#5
1
Prev: #4
|
2.9 | -1,006,569 | -19.6% |
P
S
|
4,118,321 | $8,319,008 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 5.35% | — |
#6
Prev: #—
|
4.1 | 666,666 | no change |
NEW
|
666,666 | $6,266,660 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 5.08% | 2.93% |
#7
4
Prev: #11
|
4.2 | 351,778 | 69.0% |
P
S
|
861,778 | $5,946,268 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVA
INVENTIVA SA - ...
|
Healthcare | 3.97% | — |
#8
Prev: #—
|
3.6 | 1,000,000 | no change |
NEW
|
1,000,000 | $4,650,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DCTH
DELCATH SYSTEMS...
|
Healthcare | 3.78% | 4.72% |
#9
1
Prev: #8
|
1.5 | no change | no change |
P
S
|
438,509 | $4,428,941 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABEO
ABEONA THERAPEU...
|
Healthcare | 3.74% | 5.15% |
#10
3
Prev: #7
|
1.5 | -143,242 | -14.7% |
P
S
|
830,780 | $4,378,211 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 3.58% | 4.01% |
#11
2
Prev: #9
|
1.4 | -700 | -0.5% |
P
S
|
154,300 | $4,190,788 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 2.99% | 2.79% |
#12
Prev: #12
|
3.4 | 33,822 | 69.0% |
P
S
|
82,822 | $3,501,714 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCS
OCULIS HOLDING ...
|
Healthcare | 2.95% | — |
#13
Prev: #—
|
3.2 | 172,839 | no change |
NEW
|
172,839 | $3,451,595 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 2.08% | — |
#14
Prev: #—
|
2.8 | 652,881 | no change |
NEW
|
652,881 | $2,441,775 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RGNX
REGENXBIO INC
|
Healthcare | 1.44% | — |
#15
Prev: #—
|
2.6 | 116,896 | no change |
NEW
|
116,896 | $1,683,302 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LONA
ATHIRA PHARMA I...
|
Healthcare | 0.96% | 0.62% |
#16
Prev: #16
|
0.4 | no change | no change |
P
S
|
149,279 | $1,130,042 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LENZ
LENZ THERAPEUTI...
|
Healthcare | 0.81% | — |
#17
Prev: #—
|
2.3 | 59,085 | no change |
NEW
|
59,085 | $945,360 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AARD
AARDVARK THERAP...
|
Healthcare | 0.52% | — |
#18
Prev: #—
|
2.2 | 46,408 | no change |
NEW
|
46,408 | $609,105 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZVRA
ZEVRA THERAPEUT...
|
Healthcare | 0.49% | 2.21% |
#19
5
Prev: #14
|
0.4 | -168,191 | -72.5% |
P
S
|
63,683 | $570,600 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KLRS
KALARIS THERAPE...
|
Healthcare | 0.30% | — |
#20
Prev: #—
|
2.1 | 42,053 | no change |
NEW
|
42,053 | $354,927 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
AKERO THERAPEUT...
|
Healthcare | 0.00% | 10.88% |
Sold All 😨
(Was: #3) |
0.3 | -228,884 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLT
APPLIED THERAPE...
|
Healthcare | 0.00% | 6.83% |
Sold All 😨
(Was: #5) |
0.3 | -11,285,420 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TCRX
TSCAN THERAPEUT...
|
Healthcare | 0.00% | 3.52% |
Sold All 😨
(Was: #10) |
0.3 | -1,932,304 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JSPR
JASPER THERAPEU...
|
Healthcare | 0.00% | 2.45% |
Sold All 😨
(Was: #13) |
0.3 | -1,028,806 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-24 of 24 holdings